Updated Jul. 17, 2013 at 5:49 a.m.

Premium Lock As blood pressure generic fails to materialize, Novartis ups full-year guidance

Published: 2013-07-17 05:40:00
Updated: 2013-07-17 05:49:13

Print this blog post
Novartis Novartis

Europe's biggest drugmaker says it expects to lose $2.7 billion in sales to generic competition this year, 23 percent less than it previously forecast, as it continues to benefit from Ranbaxy Laboratories's failure to market a copycat version of the Diovan hypertension drug....

Read More
Read More

WRAL Tech Wire any time: Twitter, Facebook

Copyright 2014 Bloomberg. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL Tech Wire and WRAL editors. Read more articles…

Please Log In to add a comment.

Best of TechWire Insider

Techwire Inside Partners

OUR INSIDERS

Vivek Wadhwa
Commentary
Frank Vinluan
Life science
Dr. Mike Walden
Tech economy
Scroll